Palleon Pharmaceuticals has launched with $47.6m in series A funding to commercialise cancer therapies based on technology developed at Stanford and Dundee universities.

The cancer treatment developer spun out from UCL has secured $80m in series C capital from investors including Woodford Investment Management and Syncona.

Bill & Melinda Gates Foundation will invest up to $40m in the biological drug developer, which raised $320m in an Eli Lilly-backed round two years ago.

WuXi Healthcare Ventures has led a first funding round for LifeMine Therapeutics, based on research by Harvard University profressor Gregory Verdine.

The surgery robotics developer has added $26m from investors including Cambridge Innovation Capital to complete its series A round, 14 months after closing the first tranche.

Samsung has made an $89m investment in TU Wien spinout TTTech, committing the cash through its newly established Samsung Automotive Innovation Fund.

Technical University of Munich spinout Lilium Aviation has closed a $90m series B round that included Tencent to support the development of its five-seat jet.

The data transfer technology spinout of UCLA has revealed it has raised $53m in funding since 2014, and has formed a strategic partnership with investors including Samsung and Foxconn.